Midamor

Midamor is a brand-name diuretic that contains amiloride hydrochloride. It is a potassium-sparing diuretic used to treat hypertension and edema and is commonly prescribed in combination with other diuretics to reduce potassium loss.

Amiloride inhibits epithelial sodium channels (ENaC) in the late distal tubule and collecting ducts of the kidney, reducing sodium reabsorption and potassium excretion. The resulting diuretic effect is typically mild and is especially useful when preserving potassium is desired.

It is indicated for hypertension and edema associated with heart failure, cirrhosis, or nephrotic syndrome. It is often used with a thiazide or loop diuretic to prevent hypokalemia.

In adults, the usual starting dose is 5 mg once daily, with adjustments up to 10 mg daily as needed. The usual maximum daily dose is 20 mg, and dosing should be tailored to the patient’s response and potassium level.

Contraindications include hyperkalemia and significant renal impairment (such as anuria). Cautions apply for kidney disease, older adults, and those taking potassium supplements or other potassium-sparing agents. Interactions include ACE inhibitors, ARBs, NSAIDs, and other drugs that raise potassium levels.

Adverse effects center on hyperkalemia, which can cause muscle weakness or cardiac arrhythmias. Other possible effects include nausea, dizziness, or headache.

Pharmacokinetics: Amiloride is well absorbed orally and is excreted primarily by the kidneys. Onset of diuresis occurs within hours, with effects lasting about a day. It is marketed as tablets and is widely available as a generic medication.

Historically, Midamor was one of the early potassium-sparing diuretics and remains available as amiloride hydrochloride under various brand names.